<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:379791552;
mso-list-template-ids:409365400;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:506099795;
mso-list-template-ids:-1743999392;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:533427048;
mso-list-template-ids:1990904120;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:1168910933;
mso-list-template-ids:1332800344;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4
{mso-list-id:1582257768;
mso-list-template-ids:601632110;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:1625191080;
mso-list-type:hybrid;
mso-list-template-ids:-700931990 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l6
{mso-list-id:1789205817;
mso-list-template-ids:-1874667646;}
@list l6:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l6:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l6:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.pcori.org/funding-opportunities/announcement/covid-19-targeted-pfa?utm_source=weeklyemail&utm_medium=email&utm_campaign=042120__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbuWGguys$">PCORI Funding Announcement COVID-19: Opens May 5</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">In order to respond to the COVID-19 pandemic, PCORI intends to publish a new research funding announcement to support innovative, high-impact studies that fit clearly within our core mission of patient-engaged
and patient-centered comparative clinical effectiveness research. The objectives of this announcement are to (1) strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and
healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. PCORI will encourage the use of diverse methods, including interventional studies and the use of natural experiments, to conduct research
on an accelerated timeline with the ability to complete primary outcomes collection and provide actionable findings in no longer than 12 months. Hybrid designs, which can provide insight into implementation approaches in the context of evidence generation,
will also be welcome. Applicants should be prepared to work independently and/or with PCORI to expedite dissemination of results.
<b>Please note that this funding announcement follows an expedited timeline. Applications are due three weeks following the posting of the PFA. We encourage applicants to begin working on all components of the proposal, including a detailed budget, as soon
as possible.</b> This funding announcement has <u>three targeted priority areas</u>. The research questions articulated in each of the priority areas below are not the only questions of interest; other relevant questions within these priority areas will also
be considered. The priority areas are:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo1"><b><u><span style="font-family:Palatino">Adaptations to healthcare delivery</span></u></b><span style="font-family:Palatino">: What has been the impact on patient-centered outcomes of alternative healthcare
delivery models (e.g., telehealth, hospital at home) that are being implemented in response to COVID-19? What has been learned about barriers and facilitators to their effective implementation?<o:p></o:p></span></li></ul>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo2"><b><u><span style="font-family:Palatino">Impact of COVID-19 on vulnerable populations</span></u></b><span style="font-family:Palatino">: What are effective clinical pathways to improve outcomes for the most
vulnerable and higher risk patients? What are effective system- or organizational-level responses to prevent or mitigate impact of COVID-19 in low-income and low-resource settings that serve vulnerable populations? Vulnerable populations include but are not
limited to Native Americans or Alaskan Natives, African Americans, and other racial, ethnic, or sexual and gender minorities; rural communities; incarcerated populations; people who are homeless or unstably housed; individuals with intellectual, developmental,
or physical disabilities; individuals with chronic conditions; and individuals facing increased exposure because they are unable to work remotely.<o:p></o:p></span></li></ul>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><b><u><span style="font-family:Palatino">Impact of COVID-19 on healthcare workforce well-being, management, and training</span></u></b><span style="font-family:Palatino">: What policies, practices, or programs
are effective in helping health systems quickly shift human resources, redeploy healthcare workers, and train current and new healthcare workers to fill certain healthcare delivery needs? What are effective strategies to protect the physical and/or mental
well-being of the health care workforce?<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 26, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: May 12.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020RD9_2020US.pdf__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCb1k9BR6o$" target="_blank">Pfizer: Acromegaly/Growth Hormone Excess Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Under the RFP, grants of up to $100,000 will be awarded in support of research projects with the potential to advance medical knowledge of acromegaly disease, including its complications and treatment
with pegvisomant. Projects submitted may include morbidity and mortality in patients with Acromegaly/GH Excess; laboratory investigations on effects of pegvisomant; clinical outcomes, quality of life, and patient-reported outcomes associated with monotherapy
or combination therapy, including pegvisomant; and pharmacoeconomics such as but not limited to resource utilization, patient-reported outcomes, and treatment patterns.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 28, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: May 14.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://earlychildhoodfoundation.org/__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbGO_xrws$" target="_blank">Caplan Foundation for Early Childhood Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Caplan Foundation for Early Childhood is an incubator of promising research and development projects that appear likely to improve the welfare of young children, from infancy through 7 years, in the
United States. Welfare is broadly defined to include physical and mental health, safety, nutrition, education, play, familial support, acculturation, societal integration and childcare.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Grants are only made if a successful project outcome will likely be of significant interest to other professionals, within the grantee’s field of endeavor, and would have a direct benefit and potential
national application. The Foundation’s goal is to provide <b>seed money</b> to implement those imaginative proposals that exhibit the greatest chance of improving the lives of young children,
<b>on a national scale</b>. Because of the Foundation’s limited funding capability, it seeks to maximize a grant’s potential impact.<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo4"><span style="font-family:Palatino">Early Childhood Welfare: Children can only reach their full potential when all aspects of their development — intellectual, emotional and physical
— are supported. Providing a safe and nurturing environment for infants and preschoolers is essential, as is imparting to them the skills of living in a culturally diverse world. To that end, the foundation supports programs that research best child-rearing
practices and identify models that can provide creative, caring environments in which all can children thrive.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo4"><span style="font-family:Palatino">Early Childhood Education and Play: Research shows that children need to be stimulated as well as nurtured early in life if they are to succeed in
school, work, and life. That preparation relates to every aspect of a child’s development, and everywhere a child learns — at home, in childcare settings and in preschool. The foundation seeks to improve the quality of both early childhood teaching and learning
through the development of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo4"><span style="font-family:Palatino">Parenting Education: To help parents create nurturing environments for their children, the foundation supports programs that teach parents about
developmental psychology, cultural child-rearing differences, pedagogy, issues of health, prenatal care, and diet, as well programs that provide both cognitive and emotional support to parents.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of inquiry due May 31, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 18.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-172.html__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbZohtg_k$" target="_blank">Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on
health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska
Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires September 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.pfizer.com/files/GMG_2020_IM-L-ManagementPIDisorders.pdf__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCb21b8W9o$">Pfizer: Providing Advanced Medical Support for Patients with Primary Immunodeficiency (PI) Disorders</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through this RFP it is our intent to support patient-focused programs that help patients and providers address the heightened medical and educational needs of patients with PI during this pandemic. Priority
will be awarded to projects that leverage the utilization of innovative technology platforms for distant learning to reach the intended audience with a focus on patient outreach, medical support and telework. Target audience for programs: Primary care practitioners,
specialists, infusion nurses, pharmacists, nurse practitioners, physician assistants, patient advocacy groups and the patients with PI they manage and treat. Individual projects requesting up to $250,000 will be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 8, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: May 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/mrp__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbhUxdoWw$" target="_blank">Melanoma Research Program</a><br>
<b>Idea Award</b><br>
Pre-application: June 22, 2020. Application: September 24, 2020.<br>
<b>Mid-Career Accelerator Award</b><br>
Pre-application: June 22, 2020. Application: September 24, 2020.<br>
<b>Team Science Award</b><br>
Pre-application: June 22, 2020. Application: September 24, 2020.<br>
<b>Technology Development Partnership Award</b><br>
Pre-application: June 22, 2020. Application: September 24, 2020.<br>
<b>Translational Research Award</b><br>
Pre-application: June 22, 2020. Application: September 24, 2020.<br>
<b>Translational Research Award — Collaborator Option</b><br>
Pre-application: June 22, 2020. Application: September 24, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: June 9.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.rwjf.org/en/library/funding-opportunities/2020/pioneering-ideas-2020-exploring-the-future-to-build-a-culture-of-health.html?rid=0034400001rm2ZLAAY&et_cid=2046258__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbnJG0m3g$" target="_blank">Robert
Wood Johnson Foundation: Pioneering Ideas--Culture of Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">As our current reality underscores, we live in a dynamic world—where unforeseen global events; new technologies; scientific discoveries; changes in our climate, economy, demographics; and more—continually
shape where and how we live, learn, work and play. These changes will profoundly impact health equity in our society, from our individual health and the health of our families to the health of our communities. What dramatic changes might we see in the next
5 to 15 years? What can we do today to create a better, more equitable tomorrow? We seek to answer these questions, anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in
the United States can live their healthiest life possible. Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. We are interested in ideas that address any of these four
areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress
toward a Culture of Health. We want to hear from scientists, anthropologists, artists, urban planners, community leaders—anyone, anywhere who has a new or unconventional idea that could alter the trajectory of health, and improve health equity and well-being
for generations to come. The changes we seek require diverse perspectives and cannot be accomplished by any one person, organization or sector.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Proposals will be accepted throughout the year (2020) on a rolling basis.
<span style="color:red">Med-RA deadline to receive draft documents is 10 business days before application submission.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="http://facsenate.fsu.edu/Robert-B.-Bradley-Library-Research-Grants/">FSU: Robert B. Bradley Library Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This announcement is an invitation to faculty to apply for the annual Robert B. Bradley Library Research Grants, which support the research and creative endeavors of our faculty while developing our library’s
world class collections. Bob Bradley (retired VP for Planning and Programs at FSU) has been a longtime supporter of the University Libraries, and he has advocated consistently for resources to support the centrality of the libraries that play such an important
role in the scholarly work of our faculty. In 2020-2021 the Faculty Senate Library Committee will have a total of $100,000 to support the research and creative work of faculty with new library acquisitions accessible for the whole FSU community. Please consider
preparing your brief mini-grant application over the summer, as all application materials are due in October.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 9, 2020.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.pfizer.com/files/GMG_2020RD4_2020US.pdf__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbebfBqzo$">Pfizer: Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Projects that will be considered for Pfizer support will focus on improving the care of patients by:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and treatment paradigms<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Addressing barriers to diagnosis and strategies that reduce burdens for patients and providers along the pathway to diagnosis<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Exploring strategies that empower patients to play an active role in understanding ATTR-CM and available diagnostic and treatment options<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Increasing awareness of the changing epidemiology of ATTR-CM with a focus on the prevalence of hereditary-and wild-type subtypes in the modern era<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Highlighting disease disparities for different hereditary ATTR mutations that have cardiomyopathy or mixed cardiomyopathy/neuropathy phenotypes<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Increasing awareness of at risk and undiagnosed populations with ATTR-CM with a focus on improving strategies that facilitate the diagnosis of patients early in the disease
course before advanced cardiomyopathy has ensued<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Increasing awareness of non-invasive diagnostic modalities to raise suspicion for ATTR-CM<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the diagnosis of ATTR-CM in select patients<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo5"><span style="font-family:Palatino">Supporting the dissemination of information related to the study of treatment options and monitoring response to therapy to improve patient important outcomes in ATTR-CM<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">Target audience for programs: General Cardiologists, Heart Failure Nurses, Heart Failure Specialists, Echocardiographers, Nuclear Cardiologists, Primary Care Physicians in the Local Setting. Individual
projects requesting up to $10,000 will be considered for small local/community programs. Individual projects requesting up to $20,000 will be considered for large local/community programs.
<b>Note: This RFP will remain open while funds last. Once the full budget is spent the RFP will be closed and new requests will no longer be accepted.</b><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 30, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: October 19.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-170.html__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbBKMDaag$" target="_blank">New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and
accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data
items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing,
expand the usefulness of registry-collected data to support high-quality cancer research.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The scientific scope of this FOA includes but is not limited to<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l6 level1 lfo6"><span style="font-family:Palatino">Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction and cosolidation of specific data from various types of unstructured
medical records as for example, pathology reports, diagnostic imaging, laboratory, hospital discharge forms and clinical visits;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo6"><span style="font-family:Palatino">Supplementation of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical
records (EMR).<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due November 18, 2020; June 6, 2021; November 18, 2021; June 6, 2022; and November 18, 2022; June 6, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for November 18, 2020 deadline: November 4.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-006.html__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCb8VYCACc$" target="_blank">Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia
(FH) (R61 / R33 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single site clinical trials to: (1) address barriers that impede population-level implementation of case finding and
cascade screening (i.e., blood relatives of familial hypercholesterolemia (FH) index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness,
feasibility, and scalability of family-based cascade screening programs for FH; (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using Electronic Health Records (EHRs); and (4) optimize treatment strategies
and health outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 8, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: February 23.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://macyfoundation.org/our-grantees/apply__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbSU7a-mY$" target="_blank">Macy Foundation: Medical Education Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">At the Josiah Macy Jr. Foundation, we aim to prepare future health professionals to meet the needs of the 21st century with a population that is the most diverse in U.S. history and who may live longer
than any previous generation. We are focusing on the learning environments where our future health professionals train so that they learn not only prevention and the social determinants of health but are well prepared to care for people when they are ill.
This means learning the scientific basis of disease and taking advantage of the discoveries and breakthroughs in diagnosis and treatment so that they make wise choices while providing compassionate care. We foster innovation in clinical learning environments
by investing in three areas:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://macyfoundation.org/our-priorities/promoting-diversity-equity-and-belonging__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbWKnozWI$">Promoting Diversity, Equity, and Belonging</a><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://macyfoundation.org/our-priorities/increasing-collaboration-aming-future-health-professionals__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbIn2oaoA$">Increasing Collaboration Among Future Health Professionals</a><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://macyfoundation.org/our-priorities/preparing-future-health-professionals-to-navigate-ethical-dilemmas__;!!PhOWcWs!joAELrNgLky4t8llywGmX-vvvHefrCUiW9Rq527RwC03m1_rR4SyHX8iikfBu42BwtQGcarzyiCbeswtNnU$">Preparing Future Health Professionals to Navigate
Ethical Dilemmas</a><o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Board Grants:</span></b><span style="font-family:Palatino"> Board Grants are generally one to three years in duration. Board Grants are selected three times each year at our board meetings.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Required letter of inquiry: Submit anytime.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">President’s Grants:</span></b><span style="font-family:Palatino"> President’s Grants can be given at any time and are evaluated and awarded by our president. President’s Grants usually align with our
priority areas. In general, President’s Grants are one year or less in duration and awarded amounts are no more than $35,000.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Application: Submit anytime.
<span style="color:red">Med-RA deadline to receive draft documents is 10 business days before application submission.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>